Tiny Fat Bubbles That Deliver Drugs Directly to the Liver
This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases.
Patent Number
US 11464870
Status
Active
Filing Date
October 19, 2021
Grant Date
October 11, 2022
Expiration
October 19, 2041
Claims
18
Assignee
Enhancedbio
Inventors
Hyokyoung KWON, Michaela JEONG, Hyukjin Lee, Minjeong Kim, Hansaem JEONG, Yunmi SEO
Citations
0 forward · 7 backward
What it covers
This patent claims a specific type of lipid nanoparticle (LNP) designed for delivering drugs inside the body. The LNP is made from a precise mix of four main ingredients: an 'ionizable lipid' (which changes its charge depending on acidity), a 'phospholipid', 'cholesterol', and a 'lipid-PEG conjugate' (claim 1). These tiny particles are engineered to specifically target liver tissue, including liver cells (hepatocytes) and liver blood vessel lining cells (LSECs) (claims 7, 8, 9). They can encapsulate and deliver 'anionic drugs' or 'nucleic acids' like mRNA or siRNA (claim 10, 14), which are important for gene therapy. For example, these LNPs could carry an siRNA to the liver to silence a gene causing a specific liver disease.
What it doesn't cover
- —Does not cover lipid nanoparticles that lack any of the four specific components: an ionizable lipid, a phospholipid, cholesterol, or a lipid-PEG conjugate (claim 1).
- —Does not cover lipid nanoparticles where the lipid-PEG conjugate is outside the range of 0.5 to 5 mol % (claim 1).
- —Does not cover drug delivery methods using non-anionic drugs or drugs that are not nucleic acids (claim 10).
- —Does not cover lipid nanoparticles that do not specifically target liver tissue or liver cells (claims 7, 8, 9).
- —Does not cover lipid nanoparticles with an average diameter outside the range of 30 nm to 150 nm (claim 12).
The clever bit
The clever part is the precise combination and ratios of the lipid components, especially the ionizable lipid and the small amount of lipid-PEG conjugate, which allows the nanoparticle to specifically target liver cells while efficiently encapsulating and releasing nucleic acid drugs. The specific pKa range of 6.0 to 7.0 (claim 6) is key, allowing the nanoparticle to be stable in the bloodstream but release its cargo once inside the slightly more acidic environment of a cell's endosome.
Why it matters
Targeting drugs directly to specific organs like the liver is a major challenge in medicine, especially for gene therapies. This patent offers a way to create lipid nanoparticles that are highly efficient and biocompatible, meaning they are less likely to cause harm. By specifically delivering nucleic acids to the liver, these nanoparticles could help treat serious liver conditions like ATTR amyloidosis, hypercholesterolemia, and hepatitis B virus infection (claim 16).
Real-world examples
- 1.mRNA vaccines (like Pfizer-BioNTech and Moderna COVID-19 vaccines, which use LNPs for delivery)
- 2.Gene therapies for liver diseases (e.g., Alnylam's Onpattro for ATTR amyloidosis)
- 3.Experimental treatments for hepatitis B virus
- 4.Drug delivery systems for genetic disorders affecting the liver
Generated by PatentBrief · Not legal advice · patentbrief.org
US 11464870 · 2026